CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity
Open accessPublished version of a preprint
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Cyclin-dependent kinase (CDK)4 and CDK6 are frequently overexpressed or hyperactivated in human cancers. Targeting CDK4/CDK6 in combination with cytotoxic killing therefore represents a rational approach to cancer therapy. By selective inhibition of CDK4/CDK6 with PD 0332991, which leads to early G1 arrest and synchronous S-phase entry upon release of the G1 block, we have developed a novel strategy to prime acute myeloid leukemia (AML) cells for cytotoxic killing by cytarabine (Ara-C). This sensitization is achieved in part through enrichment of S-phase cells, which maximizes the AML populations for Ara-C incorporation into replicating DNA to elicit DNA damage. Moreover, PD 0332991 triggered apoptosis of AML cells through inhibition of the homeobox (HOX)A9 oncogene expression, reducing the transcription of its target PIM1. Reduced PIM1 synthesis attenuates PIM1-mediated phosphorylation of the proapoptotic BAD and activates BAD-dependent apoptosis. In vivo, timely inhibition of CDK4/CDK6 by PD 0332991 and release profoundly suppresses tumor growth in response to reduced doses of Ara-C in a xenograft AML model. Collectively, these data suggest selective and reversible inhibition of CDK4/CDK6 as an effective means to enhance Ara-C killing of AML cells at reduced doses, which has implications for the treatment of elderly AML patients who are unable to tolerate high-dose Ara-C therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“interrupted dosing may provide an additional opportunity to use cytotoxic DNA damaging and other cell cycle targeting therapies as the cells become somewhat synchronized upon release, resulting in increased susceptibility to those compounds (Francis et al., 2017; Huang et al., 2012; Yang et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Yang et al., 2015
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640
Sauvageau, G., Thorsteinsdottir, U., Eaves, C. J., Lawrence, H. J., Largman, C., Lansdorp, P. M., & Humphries, R. K. (1995) · Genes & Development · doi:10.1101/gad.9.14.1753 · Cited by 587
Mammalian deoxyribonucleoside kinases
Arnér, E. S. J., & Eriksson, S. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00015-9 · Cited by 577
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
Thorsteinsdottir, U., Mamo, A., Kroon, E., Jerome, L., Bijl, J., Lawrence, H. J., Humphries, K., & Sauvageau, G. (2002) · Blood · doi:10.1182/blood.v99.1.121 · Cited by 347
Malumbres, M., & Barbacid, M. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.008 · Cited by 338
HOXA9 is required for survival in human MLL-rearranged acute leukemias
Faber, J., Krivtsov, A. V., Stubbs, M. C., Wright, R., Davis, T. N., van den Heuvel-Eibrink, M., Zwaan, C. M., Kung, A. L., & Armstrong, S. A. (2009) · Blood · doi:10.1182/blood-2007-09-113597 · Cited by 333
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Research works printed but not linked: 1
- Ries, SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. Ref Type: Electronic Citation.
Cited by
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 167
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 121
Targeting Pim kinases in hematological cancers: molecular and clinical review
Bellon, M., & Nicot, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01721-1 · Cited by 102
Hanaford, A. R., Archer, T. C., Price, A. C., Kahlert, U. D., Maciaczyk, J., Nikkhah, G., Kim, J. W., Ehrenberger, T., Clemons, P. A., Dančík, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3011 · Cited by 80
Metadata
- Authors
- Yang, C., Boyson, C. A., Di Liberto, M., Huang, X., Hannah, J., Dorn, D. C., Moore, M. A. S., Chen-Kiang, S., & Zhou, P.
- Affiliations
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- 1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
- Corresponding author
- Zhou, Pengbo
- Venue
- Cancer Research
- Published
- 2015-04-30
- Volume
- 75
- Issue
- 9
- Pages
- 1838-1845
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4417369
- OpenAlex
- W1994922459
- Cited by
- 62
- References
- 27
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 3
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- Pfizer
- National Institutes of Health
- National Cancer Institute (R01CA098210, R01CA120531, R01CA159925)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- CDK4/6 inhibition, palbociclib, acute myeloid leukemia, cytarabine, combination therapy, G1/S cell cycle arrest, DNA damage, apoptosis, HOXA9, PIM-1, Bad phosphorylation, xenograft tumor growth, elderly patients
- MeSH terms
- Animals, Antineoplastic Agents, Cell Line, Cytarabine, DNA Damage, DNA Replication, Humans, Phosphorylation, Piperazines, Pyridines, Transcription, Genetic, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, S Phase, Mice, SCID, Mice, Inbred NOD, Apoptosis, HL-60 Cells, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Proto-Oncogene Proteins c-pim-1, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-2486
- The paper
- Yang, C., Boyson, C. A., Di Liberto, M., Huang, X., Hannah, J., Dorn, D. C., Moore, M. A. S., Chen-Kiang, S., & Zhou, P. (2015). CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-2486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.